Biosensor chip for analyte detection and diagnostics

The medical diagnostic platform with a microfluidic sensor array chip and selective microwell gating mechanism addresses the inefficiencies of conventional diagnostics by enabling rapid, multiplexed, and cost-effective analyte detection across various specimens.

WO2026236052A1PCT designated stage Publication Date: 2026-11-12TETREL HEALTH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026231
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-01
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Conventional biological specimen diagnostics are time-consuming, limited in compatible specimen types, output formats, and number of simultaneous assays, and incur high per-test costs due to single-use devices.

Method used

A medical diagnostic platform with a microfluidic sensor array chip and diagnostics device reader that allows for rapid, multiplexed analyte detection using a reusable device, capable of handling various specimens and output formats, and includes a selective microwell gating mechanism for precise analyte analysis.

Benefits of technology

Enables rapid generation of diagnostic results within 30 minutes, reduces per-test costs, and supports multiple uses of the device, facilitating efficient and cost-effective biological specimen diagnostics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026231_12112026_PF_FP_ABST
    Figure US2026026231_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Systems, apparatuses, devices, and methods that provide a medical diagnostic platform including a diagnostics device and a diagnostics device reader. The diagnostics device includes on-board capability for performing diagnostic assay of aqueous specimens including, but not limited to, bodily fluids such as whole blood, plasma, saliva, urine, and the like. The diagnostics device reader (i.e., the device reader) engages with the diagnostics device to obtain assay results information generated by the assay(s) performed by the diagnostics device. The device reader then interpret the assay results information and output information characterizing such interpretation of the assay results information.
Need to check novelty before this filing date? Find Prior Art

Description

BIOSENSOR CHIP FOR ANALYTE DETECTION AND DIAGNOSTICS FIELD OF THE DISCLOSURE

[0001] The disclosures made herein relate generally to analyte detection and diagnostics and, more particularly, to biosensor chips configured for analyte detection and diagnostics and having one or more selectively-accessible specimen receptacles.BACKGROUND

[0002] It is well known that conventional devices and methods for performing biological specimen diagnostics often take days to weeks for results to be viewed and actioned on by a physician. Such lengthy period of time for determination and presentations of diagnostic information delays potentially critical care. Additionally, such lengthy period of time for determination and presentations is inefficient from both patient and physician standpoints even in cases where such diagnostic information is not directly associated with determining the need for potentially critical care. Still further, conventional devices and methods for performing biological specimen diagnostics are often limited in one or more of type(s) of compatible biological specimen, output format of diagnostic assay results, number of diagnostic assays that may be simultaneously completed, and number of discrete uses of a single biological specimen diagnostics device.

[0003] Therefore, implementing biological specimen diagnostics in a manner that overcomes at least the aforementioned drawbacks associated with conventional devices and methods for performing biological specimen diagnostics may be advantageous, desirable and useful.SUMMARY OF THE DISCLOSURE

[0004] The disclosures made herein are directed to implementing biological specimen diagnostics in a manner that overcomes drawbacks associated with conventional approaches for performing biological specimen diagnostics. More specifically, Systems, apparatuses, devices, and methods in accordance with embodiments of the disclosures made herein overcome drawbacks associated with type(s) of compatible biological specimen, output format of diagnostic assay results, number of diagnostic assays that may be simultaneously completed, and number of discrete uses of a single biological specimen diagnostics device. Accordingly, systems, apparatuses, devices, and methods in accordance with embodiments of the disclosures made herein provide for an efficient and effective approach for implementing biological specimen diagnostics.

[0005] Systems, apparatuses, devices, and methods in accordance with embodiments of the disclosures made herein offer a number of advantageous over conventional approaches for performing biological specimen diagnostics. One such advantage is allowing for a patient specimen to be taken and assayed with assay results generated for actionable diagnosis during a patient visit. Another such advantage is that, because biological specimen diagnostics devices in accordance with embodiments of the disclosures made herein may be used multiple times, the cost of such biological specimen diagnostics devices may be amortized to cause per-test costs to be orders of magnitude lower than currently-available rapid point-of-care (POC) diagnostics tests. Still another such advantage is that, because biological specimen diagnostics devices in accordance with embodiments of the disclosures made herein may include an array of microwells that may each be selectively tuned to a specific analyte, many different analytes can be analyzed in a single reading, thereby significantly decreasing patient specimen handling and time to results.

[0006] Systems, apparatuses, devices, and methods in accordance with one or more embodiments of the disclosures made herein provide a medical diagnostic platform including a diagnostics device and a diagnostics device reader. The diagnostics device includes on-board capability for performing diagnostic assay of aqueous specimens including, but not limited to, bodily fluids such as whole blood, plasma, saliva, urine, and the like. The diagnostics device reader (i.e., the device reader) engages with the diagnostics device to obtain assay results information generated by the assay(s) performed by the diagnostics device. The device reader then interpret the assay results information and output information characterizing such interpretation of the assay results information.

[0007] In some embodiments, the device reader has a small form factor enabling the device reader to be portable, compact, handheld, or a combination thereof.

[0008] In some embodiments, the diagnostics device include protein biosensors.

[0009] In some embodiments, at least some of the protein biosensors are synthetic protein biosensors.

[0010] In some embodiments, the protein biosensor provides redox-based signal transduction.

[0011] In some embodiments, one or more of the protein biosensors is configured to perform an assay of at least one of whole blood, plasma, saliva, and urine.

[0012] In some embodiments, the diagnostics device includes a microfluidic sensor array chip.

[0013] In some embodiments, the synthetic protein biosensors are integral with the microfluidic sensor array chip.

[0014] In some embodiments, the microfluidic sensor array chip is a Complementary Metal Oxide Semiconductor (CMOS) microfluidic sensor array chip.

[0015] In some embodiments, a microcell specimen body is engaged with an upper surface of the microfluidic sensor array chip

[0016] In some embodiments, the microfluidic sensor array chip includes selective microwell gating for enabling access to selected microwell gating.

[0017] In some embodiments, the selective microwell gating is provided for via selective generation of an electrolysis-driven gaseous bubble within a particular microwell.

[0018] In some embodiments, the microfluidic sensor array chip enables readout of assay results information via one or more of light based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output.

[0019] In some embodiments, a specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip.

[0020] In some embodiments, the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip.

[0021] In some embodiments, each reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

[0022] In some embodiments, the diagnostics device and / or the device reader includes a mapping correlating each reservoir well of the array of specimen reservoir wells to the respective plurality of the microwells of the microfluidic sensor array chip encompassed thereby.

[0023] In some embodiments, the device reader and / or other data processing apparatus provides reference wells calibration.

[0024] In some embodiments, the reference wells calibration includes statistical signal processing across reference wells.

[0025] In some embodiments, the statistical signal processing provides corrections including one or more of background subtraction, cross-contamination filtering, carryover detection, and electrolysis-induced noise compensation.

[0026] In some embodiments, the device reader and / or other data processing apparatus provides multiplexing of a single chip across multiple patients utilizing reservoir-to-microwell mapping functionality of the diagnostics device.

[0027] These and other objects, embodiments, advantages and / or distinctions of the present invention will become readily apparent upon further review of the following specification, associated drawings and appended claims.BRIEF DESCRIPTION OF THE DRAWINGS

[0028] FIG. 1 is a block diagram view of a medical diagnostic system in accordance with embodiments of the disclosures made herein.

[0029] FIG. 2 is a top view of a device reader in accordance with embodiments of the disclosures made herein.

[0030] FIG. 3 is a perspective view of the device reader shown in FIG. 2.

[0031] FIG. 4 is a fragmentary view of a diagnostics device receiving portion of the device reader shown in FIG. 2.

[0032] FIG. 5 is a perspective view of a diagnostics device in accordance with embodiments of the disclosures made herein.

[0033] FIG. 6 is a fragmentary perspective view of a diagnostics device in accordance with embodiments of the disclosures made herein.

[0034] FIG. 7 is a fragmentary top view of the diagnostics device shown in FIG. 6.

[0035] FIG. 8 is a diagrammatic view of a biosensory array in accordance with embodiments of the disclosures made herein.

[0036] FIG. 9 is a schematic view showing a methodology for engineering a Tyrosine molecule into a protein biosensor in accordance with embodiments of the disclosures made herein.

[0037] FIG. 10 is a schematic view of an FG-EGFET derived from an n-type enhancement mode MOSFET transducer.

[0038] FIG. 11 is a diagrammatic view of a microwell flow control mechanism in a closed configuration in which flow of a fluid to a biosensor in a lower portion of a microwell is inhibited.

[0039] FIG. 12 is a diagrammatic view of the microwell flow control mechanism of FIG. 11 in an open configuration in which flow of a fluid to the biosensor in the lower portion of the microwell is enabled.DETAILED DESCRIPTION

[0040] The disclosures made herein are directed to various aspects of a medical diagnostic platform. The medical diagnostic platform may be implemented as one or more systems, apparatuses, devices, methods, or combinations thereof that enable rapid POC diagnostics. Such rapid POC diagnostics beneficially makes information derived from many standard biological assays performed via the medical diagnostic platform to be available to a physician during an office visit in which a required specimen or specimens is received. For example, in some embodiments, the time from taking the specimen(s) to when results of the diagnostics are available is 30 minutes or less. This is in contrast to conventional specimen diagnostics that take days to weeks for assay results to be generated and then made available to a physician.

[0041] Medical diagnostic platform in accordance with embodiments of the disclosures made herein include platform components (e.g., system, device, reader, and method or combinations thereof) that facilitate performing diagnostic assays on biological specimens, assessing / interpreting results of such assays, and outputting information derived from the assessment / interpretation. Systems, devices, apparatuses (e g., readers), and methods in accordance with embodiments of the disclosures made herein are applicable to various different types of specimen, which may be an aqueous bodily fluid. Examples of such an aqueous bodily fluid include, but are not limited to, whole blood, plasma, saliva, urine, and other specimens for which an available assay (i.e., specimen known thereto) is available.

[0042] As shown in FIG. 1-4, a medical diagnostic system 100 in accordance with embodiments of the disclosures made herein may include a diagnostics device 105 and a diagnostics device reader 110 (i.e., the device reader 110). The diagnostics device 105 is configured for carrying out the aforementioned diagnostic assays on biological specimens and the device reader 110 is configuredfor carrying out the aforementioned assessing / interpreting results of such assays and outputting information derived from the assessment / interpretation. Preferably, as shown, the diagnostics device 105 and the device reader 110 are separate (i.e., standalone) units that are engageable with each other. For example, the device reader 110 may include a receptacle 115 within which the diagnostics device 105 may be physically engaged for causing a communications interface to be established between the diagnostics device 105 and the device reader 110. In some embodiment, the diagnostics device 105 and the device reader 110 may be unitary components of an apparatus that jointly provides functionalities of the diagnostics device 105 and the device reader 110.

[0043] Referring to FIGS. 5-8, the diagnostics device 105 includes a microfluidic sensor array chip 120 and a specimen reservoir structure 125. An array of microwells 135 are exposed at the upper surface 130 of the microfluidic sensor array chip 120. The microwells 135 may be made using any suitable semiconductor fabrication technique. For example, the microwells 135 may be made using Very Large Scale Integration (VLSI) fabrication technique which allows for up to many millions of microwells to be fabricated, depending on parameters such as die size, microwell density, and microwell diameter. Accordingly, in accordance with embodiments of the disclosures made herein, the microwell fabrication techniques advantageously enable a specimen sample to be as small as a drop of blood (~30uL) and as large as a typical blood panel specimen volume ~400uL and, additionally, enable microfluidic sensor array chips to offer high-throughput, reusable diagnostic testing, and leveraging of an array of up to 1 million (or more) individually addressable microwells.

[0044] The specimen reservoir structure 125 is overlays an upper surface 130 of the microfluidic sensor array chip 120. The specimen reservoir structure 125 is engaged with the upper surface 130 of the microfluidic sensor array chip 120 in a manner that forms a fluid-tight seal between the upper surface 130 of the microfluidic sensor array chip 120 and a mating surface of the specimen reservoirstructure 125. As shown, the specimen reservoir structure 125 may include a single specimen cavity 132 into which a specimen sample may be delivered and retained for allowing assay functionality to be performed with an underlying portion of the microfluidic sensor array chip 120. The specimen cavity 132 encompasses an array of all of the microwells 135 that are available for performing assay functionality by the microfluidic sensor array chip 120. For example, such microwells 135 that may be used for performing assay functionality may be those that are exposed to the specimen cavity 132, where some microwells 135 are covered by (i.e., located under) the portion of the specimen reservoir structure 125 that is engaged with the upper surface 130 of the microfluidic sensor array chip 120. In some other embodiments, the includes a plurality of specimen cavities 132 each encompassing a subset of the array of all of the microwells 135 that may be used for performing assay functionality into which a specimen sample may be delivered and retained for allowing assay functionality to be performed with an underlying portion of the microfluidic sensor array chip 120.

[0045] As best shown in FIG. 6, a bottom portion of each of the microwells 135 may include a biosensor 140. The biosensor 140 may be a protein biosensor, synthetic biosensor, synthetic protein biosensor, or other type of biosensor. The biosensor 140 of each of the microwells 135 is selective of and specific to a particular analyte (i.e., target component of a specimen sample) and may be tuned to respond within a known concentration region of the particular analyte. Each biosensor 140 may be formed by any suitable biosensor fabrication technique within a respective one of the microwells 135 such as, for example, inkjet-printed, screen printed, drop casted, flow deposited, lithographically patterned, or combinations thereof.

[0046] Still referring to FIG. 6, a portion of the microfluidic sensor array chip 120 below a respective biosensor 140 is a respective sensor of the microfluidic sensor array chip 120 that senses chemical reaction of an analyte reacting with exposure to the respective biosensor 140 (i.e., an analytedetection signal) and outputs a corresponding signal - i.e., chip sensor 121. In some embodiment, the chip sensor 121 may be a redox chip sensor that senses one or more types / configurations of redox molecule.

[0047] The chip sensor 121 receives an assay result signal (i.e., a transient analyte detection signal) in response to detection of a target analyte by the respective biosensor 140 and produce (e.g., transduce) an output signal corresponding to the assay result signal. Accordingly, an array of assay sites (i.e., adjacent microwell locations) spanning a cluster of the microwells 135 and each having a common biosensor configuration (e.g., analyte assay functionality) may be provided to form localized detection zones on the microfluidic sensor array chip 120 for specific analytes. The size and placement of each assay site may be configured to minimize overlap, thereby enabling dense multiplexing of different protein biosensors across the microfluidic sensor array chip 120.

[0048] The microfluidic sensor array chip 120 may be of the Complementary Metal Oxide Semiconductor (CMOS) type. The microfluidic sensor array chip 120 may be configured in a number of known different ways to perform reception of information characterizing analyte detection (i.e., the analyte detection signal) and to perform transformation of that information characterizing analyte detection to a suitable output signal. In one embodiment, the microfluidic sensor array chip 120 is configured as an electrochemical chip that uses a biosensor to detect an analyte when a local electrochemical change occurs within a respective microwell (i.e., a biosensor reaction well) and a transient analyte detection signal generated by the local electrochemical change is converted (i.e., transduced) by the output signal portion of the electrochemical chip into a corresponding an output signal (e.g., an analog signal). In another embodiment, the microfluidic sensor array chip 120 is configured as light chip that uses a biosensor to detect an analyte and to produce a photon (i.e., analytedetection signal) that is then detected by an image sensor in the chip and converted by the output signal portion of the light chip to an output signal.

[0049] All or a portion of the microwells 135 may include a selective microwell flow control mechanism 145 that enables microfluidic flow of a specimen sample within a particular one of the microwells 135 to be selectively enabled or inhibited such as via CMOS-controlled electrolysis bubble gating functionality for allowing the microfluidic sensor array chip 120 to isolate analyte reactions with precision. The selective microwell flow control mechanism 145 advantageously allows certain ones of biosensors accessible to a respective specimen cavity 132 to be exposed to a specimen sample within the respective specimen cavity 132 while inhibiting certain other ones of the biosensors accessible to the respective specimen cavity 132 from being exposed to the specimen sample within the respective specimen cavity 132. That is, when in a first state of operability (e.g., activated), the selective microwell flow control mechanism 145 of the particular one of the microwells 135 blocks (i.e., inhibits flow of) the specimen sample within the respective specimen cavity 132 from being able to flow through the particular one of the microwells 135 to the biosensor 140 therein and the reverse is true when the selective microwell flow control mechanism 145 of the particular one of the microwells 135 is in a second state of operability (e.g., not activated).

[0050] When selected one(s) of the microwells 135 are open to interact with the specimen sample within the respective specimen cavity 132 (e g., associated selective microwell flow control mechanism 145 is activated), the biosensor 140 of each open microwell 135 binds to their targeted analyte(s) and produce an analyte detection signal - i.e., a signal that may be either an electrochemical or photon based signal. The analyte detection signal is then transduced by the output signal portion 121 of the microfluidic sensor array chip 120 at the bottom of the microwell 135 as an analog signal. The analog signal may then be converted to a digital signal for analysis by the device reader 110.The device reader 110 may make diagnostic calls based on the transient signal of each microwells 135 and by which each microwell 135 is producing signals and may transmit that signal information.

[0051] Referring now to FIG. 8, biosensors of different configurations (e.g., for detecting different analytes) are used to enable multi-patient use of an array of microwells - e.g., the microwells 135 discussed herein. The biosensors may be provided in respective clusters - i.e., biosensor cluster A, biosensor cluster B, and biosensor cluster C. For example, biosensors of biosensor cluster A detect a first analyte, biosensors of biosensor cluster B detect a second analyte chemically different than the first analyte, and biosensors of biosensor cluster C detect a third analyte chemically different than the first and second analytes. Within each cluster, a selected unique subset of the microwells of such cluster may be used for performing assay functionality for specimens of a plurality of different patients. For example, via selective microwell access via a microwell flow control mechanism (e.g., the microwell flow control mechanism 145 discussed herein) of each of the microwells 135, a first selected unique subset of the microwells 135A may be used for performing assay functionality for specimens of a first patient. Thereafter, with the specimen cavity of a specimen reservoir structure that is integral with the an array of microwells (e.g., the specimen cavity 132 of a specimen reservoir structure 125 discussed herein) being cleaned and sterilized, a second selected unique subset of the microwells 135B different than the first selected unique subset of the microwells 135A may be used for performing assay functionality for specimens of a second patient. Beneficially, the diagnostic assay for each patient may have multiple microwells (i.e., the respective subset of a plurality of the microwells 135) for enabling statistical capabilities. Additionally, reference microwells may be used for signal analysis.

[0052] In view of the disclosures made herein, a skilled person will understand that the aforementioned aspects of diagnostics devices and / or diagnostics device readers in accordance withembodiments of the disclosures made herein provide a platform architecture offering a myriad of beneficial attributes that enables cost-effective reuse of a single microfluidic sensor array chip and / or diagnostics device across dozens to hundreds of patients thereby dramatically reducing per-test cost while maintaining analyte specificity and signal fidelity. A first one of these attributes is that the diagnostics device and / or the device reader may maintain a mapping correlating each reservoir well of an array of specimen reservoir wells to the respective plurality of the microwells of the microfluidic sensor array chip encompassed thereby. A second one of these attributes is that the device reader may maintain a biosensor map that links each microwell to its associated biosensor type. A third one of these attributes is that that device reader may utilize built-in reference microwells of a diagnostics device (e.g., microwells intentionally left blank and interspersed throughout an array) to calibrate and normalize the signal. A fifth one of these attributes is that in view of the different protein biosensors can be flowed, printed, reacted, or drop-casted over the microfluidic sensor array chip and only microwells that are open wells will have that particular biosensor chemistry exposed to the bottom of the microwell where the reaction and sensing takes place. A sixth one of these attributes is that many different biosensors selective and specific to a particular type of analyte may be added to selective wells so that only one type of biosensor is present in a single well and that location is known. A seventh one of these attributes is that many microwells may contain the same biosensors and be opened and closed for different patient specimens to avoid electrode re-use (e.g., to avoid cross contamination and patient specimen carry-over). An eighth one of these attributes is that the same microfluidic sensor array chip may be used with multiple patient specimens (i.e., with adequate specimen flushing) but the microwell sensors are only used a single time as they were closed with previous patient specimens. A ninth one of these attributes is that that, during operation, only a subset of a set of microwells may be exposed to the specimen sample by using the selective microwell flowcontrol mechanism of only that subset of microwells to allow flow of the specimen sample (i.e., opening gates of specific microwells), while using the selective microwell flow control mechanism of the remaining microwells of the set to preclude flow of the specimen sample to thereby preserve biosensors of such remaining microwells in an unused state. A tenth one of these attributes is that, for statistical power, multiple microwells having the same configuration of biosensor may be opened for allowing flow of a specimen sample to thereby generate a rich data stream for difficult-to quantity analytes. An eleventh one of these attributes is that, after use, microwells used for assessing a specimen sample may be washed and resealed, allowing the microfluidic sensor array chip to be used again for subsequent patient specimens.

[0053] Discussed now are constituent components that may be integral with systems, apparatuses, devices, methods, or combinations thereof in accordance with embodiments of the disclosures made herein.

[0054] BIOSENSORS

[0055] Proteins

[0056] Protein biosensors are engineered or naturally occurring proteins designed to detect specific molecules (analytes) through highly selective biological interactions. These proteins undergo a measurable physical or chemical change such as a shift in fluorescence, redox state, or conformation upon binding to their target. By coupling these changes to a signal transduction mechanism, protein biosensors can translate molecular recognition events into quantifiable outputs. Their versatility, tunability, and high specificity make them ideal for diagnostics.

[0057] Receptor Proteins: Bind specific ligands or small molecules with high affinity. Examples include GPCRs (G-protein-coupled receptors) used for hormone or neurotransmitter sensing, Periplasmic binding proteins (PBPs) used in bacterial nutrient sensing (e.g., glucose, phosphate). Mechanism of detection through a conformational change upon ligand binding, often linked to fluorescence or electrochemical change.

[0058] Enzymes: Enzyme catalyze reactions with specific substrates and include examples like Glucose oxidase (Used in glucose sensors (produces H2O2 —> redox signal)), Urease, creatinine deaminase (Used for metabolic panel sensing), Choline oxidase, lactate oxidase, cholesterol oxidase. Its mechanism converts target into product with measurable optical or redox signal.

[0059] Transcription Factors: (TF) Bind to specific DNA regions only in the presence of a target analyte (ligand-activated), Examples include TetR, LacI, AraC which are Small-molecule-sensitive repressors / activators. Their mechanism is from conformational change and can produce fluorescent or transcriptional output in a synthetic circuit.

[0060] Fluorescent Proteins (FPs): FPs emit light when excited or change brightness / color in response to an analyte. Examples include GFP, mCherry, mVenus and are Circularly permuted FPs (cpFPs) fused to receptors / enzyme domains for FRET or intensity-based sensing. Mechanism includes structural changes affect chromophore environment which produces a signal readout.

[0061] Redox-Active Proteins: Undergo changes in oxidation state upon interaction with a target. Examples include Cytochromes, ferredoxins, and azurins. Their mechanism Redox reaction produces a measurable current or potential on electrode.

[0062] Antibodies / Antibody Fragments: They bind very specifically to proteins, viruses, or other antigens in either a full antibodies (IgG), Fab fragments, scFvs, or nanobodies format. Their mechanism of a binding event produces signal transduction via optical or electrochemical method.

[0063] Aptamer-Binding Fusion Proteins: Proteins fused to aptamers or RNA-binding domains that alter output upon ligand binding. Examples include MS2 coat protein fused to reporters, or riboswitch-protein hybrids. Their mechanism includes RNA conformation change or binding interaction affects attached reporter.

[0064] Allosteric Protein Switches (Engineered): Protein domains engineered to switch conformation when the analyte is present. Examples include modular switches combining receptor + reporter (e.g., bio-switches). Mechanism includes llosteric coupling between input (binding) and output (signal).

[0065] Bioluminescent Proteins: Emit light without external excitation (great for dark-field or CMOS integration). Examples include firefly luciferase, NanoLuc, Antares, Renilla luciferase. Mechanism includes Enzyme catalyzes reaction with luciferin emits photons (usually 460-630 nm).

[0066] Protein-Based Ion Sensors: Bind or respond to specific ions. Examples include Calmodulin (Ca2+sensing), valinomycin-fused proteins (K+), synthetic protein-ionophores mechanism is conformational change upon ion binding which is paired with optical or electrochemical transducer.

[0067] Signal Transduction (Redox)

[0068] The biosensor protein comprises a redox-active moiety whose electron transfer to an electrode is structurally gated. In the unbound state, the moiety is conformationally sequestered, physically or electrostatically insulated from redox coupling. Upon analyte binding, a structuralrearrangement occurs that exposes and activates the redox site, enabling direct or mediator-assisted electron transfer to the embedded transducer. This conformation-specific redox activation forms the basis of the detection signal.

[0069] Referring to FIG. 9, a molecule like Tyrosine can be engineered into the protein biosensor so that when the analyte is not bound, the tyrosine is not able to act as an 02 acceptor. Once the analyte preferentially binds, the tyrosine is exposed and can catalyze a redox reaction and a redox reaction can be transduced in a measurement circuit as a voltage shift of 0.5V compared to a Ag / AgCl reference potential.

[0070] Pre-Binding State (Redox-Inactive Conformation):

[0071] Before the analyte is present, the protein biosensor is in a resting or “closed” conformation. In this state. The redox-active group (e.g., engineered tyrosine, quinone, or flavin moiety) is either: 1. Sterically buried inside the hydrophobic core of the protein, or 2. Electrostatically shielded from solvent and the electrode surface, or 3. Conformationally misaligned so its redox orbital cannot couple with the electron transfer pathway. Additionally, key residues or domains may form internal hydrogen bonds or disulfide linkages that inhibit access of solvent or redox mediators to the redox site. The protein orientation on the surface (e.g., tethered by His-tag or cysteine to gold / Pt) ensures that the redox group is not in direct contact with the electrode or its electron pathway. This results in no electron transfer and the redox signal remains off or at baseline.

[0072] Post-Binding State (Redox-Active Conformation): Upon analyte binding a conformational switch occurs driven by either domain rotation, loop movement, or hinge bending that repositions the redox-active group into a solvent-accessible and electrochemically favorable orientation. This conformational change: 1. Exposes the redox group to the electrode interface or embedded mediator,2. Aligns electron orbitals for efficient transfer (e.g., pi-stacking or hydrogen bonding changes), 3. Displaces inhibitory interactions (e.g., loop shielding or ionic cages). If a redox mediator is present (e.g., ferricyanide, quinone, phenazine), the redox site becomes catalytically coupled, allowing continuous cycling. This results in redox activity that is “gated” by analyte binding, enabling signal amplification with high specificity.

[0073] PROTEIN IMMOBILIZATION INTO MICROWELL

[0074] Covalent immobilization of protein biosensors onto the CMOS chip surface (typically platinum or gold electrodes) ensures stable, long-term attachment and precise spatial localization of the sensing elements. This is commonly achieved by functionalizing the metal surface with selfassembled monolayers (SAMs) bearing reactive groups such as thiols, carboxyls, or maleimides, which can form strong covalent bonds with engineered residues on the protein, such as surface-exposed cysteines or lysines. This anchoring strategy minimizes protein leaching during operation, maintains bioactivity, and supports high-density patterning within microwells, enabling reliable signal transduction in electrochemical or optical detection modes.

[0075] Polymer or hydrogel matrix: To enable stable and selective detection of analytes in whole blood, protein biosensors are immobilized at the base of each microwell using a biocompatible hydrogel matrix. This hydrogel serves a dual function: it acts as a scaffold for anchoring the biosensor proteins in a defined spatial configuration, and as a selective permeability barrier that allows small molecules like glucose, urea, or cytokines to diffuse through while excluding larger components such as red blood cells (RBCs). Common hydrogel materials include polyethylene glycol (PEG) hydrogels, which are highly tunable and resistant to biofouling, as well as alginate or polyacrylamide, which offer controlled pore sizes ranging from a few to hundreds of nanometers. These materials can befunctionalized with reactive groups (e.g., NHS esters, acrylates) to covalently attach engineered proteins, ensuring long-term stability. When integrated into CMOS-compatible microstructures, the hydrogel preserves a clean sensing interface and maintains molecular access to the sensor while physically filtering out cellular debris and interference from whole blood.

[0076] CHIP

[0077] As discussed herein, the chip consists of a packaged die (i.e., microfluidic sensor array chip) and flowcell (i.e., specimen reservoir structure). The packaged die interfaces with the reader and sends transient signal data to the reader. The flowcell holds the patient specimen.

[0078] Electrochemical Chip

[0079] Front end: An electrochemical array sensor integrates a dense grid of individually addressable electrodes on a CMOS or VLSI chip to detect biochemical signals such as redox reactions. Each microwell in the array contains one or more electrodes that serve as the interface between the biological specimen and the electronic readout. To transduce biochemical activity into an electrical signal, each pixel incorporates a Floating-Gate Extended-Gate Field-Effect Transistor (FG-EGFET), a specialized type of FET architecture ideal for large-scale biosensor arrays. In this design, the platinum sensing electrode acts as the extended gate and is capacitively coupled to the floating gate of the underlying FET. When a redox-active analyte or engineered biosensor protein induces an electron transfer event at the electrode surface, the resulting change in interfacial potential is transmitted through the dielectric to modulate the channel conductivity of the transistor. The signal is then routed through a readout chain that includes row / column multiplexers, amplification stages, and analog-to-digital converters (ADCs), enabling high-resolution, low-noise digital output. This FG-EGFET configuration minimizes leakage current, allows separation of sensing and transductionfunctions, and supports robust performance in biological fluids like whole blood. With full CMOS compatibility, the array can scale to millions of microwells for massively parallel, label-free biosensing applications in diagnostics, synthetic biology, and high-throughput screening.

[0080] Referring to FIG. 10 is a schematic of an FG-EGFET taken from illustration of an EG-FET sensing concept using the example of n-type enhancement mode MOSFET transducer. Extended gate (EG) electrode equipped with a sensing layer is electrically connected to the gate terminal of the FET transducer. Biasing of the reference electrode and FET transducer enables potentiometric monitoring of surface potential shifts due to the interaction between the sensing layer and target analyte in electrolyte medium, (a) Abbreviations: GND - ground, D - drain, G - gate, S - source, (b) Symbols: VR - reference electrode voltage, VGS - gate-to-source voltage, VDS - drain-to-source voltage, ID -drain current. Zeljko Janicijevic, Trang-Anh Nguyen-Le, Larysa Baraban, Extended-gate field-effect transistor chemo- and biosensors: State of the art and perspectives, Next Nanotechnology, Volumes 3-4, 2023, 100025, ISSN 2949-8295, https: / / doi.Org / 10.1016 / j.nxnano.2023.100025.

[0081] Back end: The backend processing forms the microwell and the electrodes which perform both the electrolysis bubble control and the sensing. The sidewalls can be made of a variety of materials commonly used in MEMS processing. Choice of the materials allows one to control for well size, shape, aspect ratio, surface hydrophobicity. Common materials used to create microwell structures on CMOS chips include SU-8 (for high-resolution, permanent wells), PDMS (for flexible, removable layers), silicon di oxide / silicon nitride (for shallow etched wells), polyimide (for thermally stable, patterned polymers), PMMA or thermoplastics (for prototyping via molding or milling), and glass / quartz (for optically transparent bonded layers).

[0082] FIG. 11 is a diagrammatic view of a bubble gate (i.e., a microwell flow control mechanism) in a closed configuration in which flow of a fluid to a biosensor in a lower portion of a microwell is inhibited. FIG. 12 is a diagrammatic view of the bubble gate in an open configuration in which flow of a fluid to the biosensor in the lower portion of the microwell is enabled.

[0083] Packaging: Packaging uses standard CMOS packaging which usually includes a ceramic or FR4 base, wirebonds, and wire bond encapsulation. The backside of the package may have contacts for electrical interface to the reader.

[0084] Reference Electrode: The reference electrode is used as a comparison to electronically determine if the active (or sense) electrodes are transduction real or background signal. The reference electrode can be added as a separate device in the flowcell or integrated into the chip itself. It may be beneficial from a signal analysis perspective to have a reference electrode positioned equidistant to all active electrodes. The reference electrode can be made of many different materials ranging from a conductive noble metal like Au or Pt but it can also be made of known industry standard reference electrode materials like Ag / AgCl.

[0085] Light (Photon) Chip

[0086] Front end: The front end of the chip may be an off the shield CMOS image sensor. The chip may need to be compatible with a glass cover which can direct light into the pixels of the image sensor.

[0087] Glass Cover: A glass cover may contain the etched microwells and electrolysis driven microwells. Conductive traces may need to be routed to the edge of the glass cover to control the electrolysis.

[0088] Packaging: Packaging may enclose any electronics or circuitry to control the electrolysis on the glass cover. It may also allow for a seamless integration between the glass cover and the image sensor so that any light signal generated at the bottom of the wells can be detected by the image sensor.

[0089] Flowcell: The flowcell (i.e., specimen reservoir structure ) is a plastic reservoir which holds the patient specimen. It is bonded to the surface of the chip die using adhesive or is pressed and held from the side using an O-ring or thermoplastic elastomer. The flowcell pictured in this overview shows a reservoir capacity of 30uL to hold a single drop of whole blood up to a reservoir of 400uL which holds a standard volume of patient whole blood. The flowcell can be made of biocompatible injection moldable materials like PC, ultem (polytherimide), or other plastics or glass. The top of the flowcell can contain holes for a pipette or interface to a fluidic transport system.

[0090] Bulk

[0091] Patient Specimen

[0092] The bubble-gate CMOS biosensor chip is compatible with a wide range of patient specimen fluids, enabling versatile diagnostic applications across care settings. It can detect analytes in whole blood, plasma, and serum, making it ideal for core metabolic and immunological testing. The chip is also adaptable to non-invasive fluids like saliva, urine, sweat, and tears, which are useful for hormone monitoring, drug testing, and infectious disease detection. With expanded biosensor design, the system can extend to specialized fluids such as cerebrospinal, amniotic, synovial, and peritoneal fluids, allowing for diagnostics in neurology, prenatal care, and oncology. Finally any aqueous system that has small molecules of interest could be used like water treatment and contaminate analysis.

[0093] Wash and storage fluid

[0094] The wash and storage fluid needs to flush previous specimen while also maintaining the chip’s surface stability. Phosphate-buffered saline (PBS) supplemented with 0.01-0.05% Tween-20 or Triton X-100, a mild non-ionic surfactant that helps clear proteins and cells without disrupting bubble stability. 0.1% BSA can be added as a protein stabilizer to maintain biosensor integrity and prevent nonspecific adsorption. This buffer maintains ionic conductivity for redox sensors and supports hydration between uses.

[0095] Redox signal amplification and electron shuttling

[0096] For the electrochemical version of the chip, the wash and storage solution might also contain redox signal enhancing chemicals which can be catalyzed to amplify the redox signal. Table 1 characterizes molecules that can be integrated into the biosensor and the amplification system of molecules in the bulk which can shuttle electrons and enhance signal upon binding.

[0097] TABLE 1RedoxPotentia ichanism ofMolecule Amplification 1 (V vs Action NotesSystem SHE)HRP + H2O2ElectronFerroce GOx + Glucose transfer upon Stable, reversible redox ne & Produces H2O2, -0.4-0.7 conformation couple, widely used in Derivati which Pt can oxidize V al shift biosensorsvesHRP + H2O2GOx + Glucose —>Produces H2O2, RedoxQuinones (e.g., which Pt can oxidize activeBenzoquinone, cofactor, Can be engineered into Naphthoquinon Laccase / Tyrosinas-0.1-0.3 accepts / dona protein binding sites e (O2 as electrone) V tes electronsacceptor)Flavins Laccase / Tyrosinas Flavin-based Found naturally in many (e g., FAD, e (O2 as electron —0.2 to redox redox enzymes FMN) acceptor) 0.0 V reactionsPhenothiazineDerivatives Electron(e.g., Toluidine mediator, Good for protein coupling Blue, Azure A) HRP + H2O2 -0.2-0.3 changes state due to electrostaticV upon analyte interactionsbindingVaries (- RedoxUsed in natural electron Iron-Sulfur 0.4 to active transfer systems (e.g., in Clusters 0.4 V) metalloprote respiration)insPrussian Blue & GOx + Glucose Electron Used in electrochemical Derivatives Produces H2O2, -0.2-0.3 shuttling & sensors for enhanced signal which Pt can oxidize V amplificationTyrosine / T Laccase / Tyrosinas Enzymatic Can be engineered into yrosyl e (O2 as electron -0.5 V electron protein active sites. 02 as Radical acceptor) transfer electron acceptor CobaltComplexes Metal-based Works well in biological (e g , —0.6 to redox electron transfer reactions Cobaltocene, 0.2 V mediatorVitaminB12)

[0098] The signal chain is as follows:

[0099] (1) Analyte Recognition and Binding: The synthetic protein biosensor includes a specific binding domain (e.g., antibody fragment, aptamer, or ligand-binding motif) that selectively binds to a target analyte (A), such as a small molecule, metabolite, hormone, or protein. This binding induces a conformational change in the biosensor that exposes or activates a redox-active domain: Biosensor+ Analyte (A) — Biosensor* A Complex.

[0100] (2) Redox Molecule Integration and Activation: The biosensor is engineered with an immobilized redox-active moiety, such as a tyrosine derivative (e.g., 3,4-dihydroxyphenylalanine or other redox-capable aromatic residue) or synthetic quinone analog. Upon analyte binding, the redox group becomes catalytically exposed or electron-transmissive. This reaction generates a quantifiable redox signal (change in current or potential) at the electrode interface: Tyrosinered^(Analyte Binding) — Tyrosineox+2e+2H+.

[0101] (3) Redox Cycling / Signal Amplification: To enhance signal output, the system can incorporate a cofactor or redox mediator (M) in the hydrogel or surface chemistry that participates in redox cycling. This amplifies signal output with each binding event through turnover of the mediator, enabling continuous electron release as long as analyte is present and binding occurs: Mox+Tyrosinered— > red+Tyrosineox (biosensor reaction) Mred^Mox+2e +2H (at electrode).

[0102] (4) Electron Capture and Transduction at Electrode: Electrons generated from redox-active groups are transferred to the working electrode embedded at the base of the microwell (e.g., Pt or Au), where they are detected by the CMOS readout system. The signal can be measured as current (amperometry), potential shift (potentiometry), or impedance, depending on the configuration: Electrode Reaction: 2e-+2H+—> Signal.

[0103] Reader

[0104] The reader is a small and compact chip reader that also transmits the diagnostic information to an information system (like LIS, LIMS, or other networked system). The physical components of the reader contains a processing unit, chip interface electronics, communication electronics (Wi-Fi or Bluetooth), USB-C, storage, EMC protected enclosure, and a lid to protect the lid during use. As the reader reads the transient signals of the wells, for a particular well of known biosensor and signal analyte, it compares the measured signal to a known reference line. If the signal is greater than the reference line then it means that analyte is present. The signal shape can give concentration information.

[0105] Electrochemical Chip: For the electrochemical version of the reader, an interface to the chip packaging consisting of pogo pins or leaf spring connectors make contact to the chip’s contacts. Analog or digital signals can then be read and interpreted.

[0106] Light Chip: For the light based version of the chip, a permanent image sensor is fixed in the reader. The glass cover which contains the microwells is placed over the image sensor and a signal is generated in the glass cover and read by the image sensor. The reader cover may be opaque to keep background light to a minimum.

[0107] METHOD OF OPERATION

[0108] Bubble Gate Control mechanism

[0109] Electrolysis-driven bubbles (i.e., selective microwell flow control mechanism) are used in microfluidic systems to selectively block channels or seal microwells by generating gas (FL and O2) at a microelectrode through water electrolysis. When a voltage is applied, a bubble forms and growsuntil it occludes the fluid path, functioning as a gate or valve. These bubbles can be maintained with continuous or pulsed current and are typically pinned in place using hydrophobic surfaces or structured features. To reopen the path, the bubble can be shrunk via passive dissolution, reverse biasing, or geometry-assisted removal. This method enables compact, low-power, and valve-less fluid control, with key design factors including electrode material, well dimensions, surface chemistry, and compatibility with CMOS and biological fluids.

[0110] When a well is intended to be closed, the reader applied a bias voltage (~3-5 V) is applied between the working and counter electrodes in an electrolyte (often a buffered solution). Gas nucleates and forms a bubble at the electrode. As the bubble grows, it occludes the channel or well. To maintain the bubble in the microwell, a continuous current or pulsed electrolysis (which is more energy-efficient) is given. The electrode sensor below the electrolysis electrodes can be monitored to ensure that the microwell is closed. If the sense sensor shows a conductive path to the reference electrode then the bubble has failed and that well will be masked off.

[0111] Hydrophobic surfaces or physical features (e.g., ring electrodes, micropillars) help pin the bubble in place. The microwell surface above and below the electrolysis electrode can be coated in materials like Teflon, Parylene, Hydrophobic polymers, PDMS, or SU-8 to be compatible with manufacturing techniques while also ensuring bubble placement.

[0112] The microwell can be reopened by the reader by shrinking the bubble by either (1) stopping the current (passive dissolution), (2) applying a reverse bias (gas recombination), or (3) moving the bubble away (e.g., via geometry-driven detachment).

[0113] Signal transduction

[0114] Electrochemical Chip: For the electrochemical chip, signal transduction can be achieved by implementing a high impedance circuit connecting the reference electrode to the sense electrode. The reader can read through the active wells and see the current redox potential of the well. If the redox potential in the well is different than the reference electrode and empty reference wells, then the signal can be interpreted as a binding event. The transient signal shape can then be used to determine analyte concentration in the well.

[0115] Light Chip: For the light chip, the bioluminescent intensity is captured by the CMOS image sensor. Its transient intensity curve is determined if there is an analyte present and its concentration.

[0116] Applications

[0117] Although this technology was originally scoped for compatibility with a long haul space mission environment, this technology could also be used on earth and provide rapid point of care (POC) diagnostics. The disclosures made herein encompass both earth and extraterrestrial (i.e., space) applications where some target analytes are shared and some are specialized for the application. Systems, apparatuses, devices, and methods in accordance with embodiments of the disclosures made herein are uniquely suited for space is its regenerative biosensing capability: the protein sensors are engineered to be replenishable via onboard bacterial expression systems, allowing crews to grow fresh biosensor batches as needed using synthetic biology. This regenerative approach reduces the need for resupply missions, supports long-duration spaceflight, and aligns with circular life-support systems making the diagnostic platform both autonomous and sustainable for future deep-space missions.

[0118] A medbay in space is a critical infrastructure component for ensuring crew health and mission success during long-haul spaceflight, where access to Earth-based medical support isimpossible. To sustain medical operations over months or years, the medbay must rely on recyclable or regenerative diagnostic tools and reagents, minimizing waste and resupply needs. This includes closed-loop microfluidic systems, sterilizable equipment, and reusable / recyclable assay fluids. Continuous health monitoring in such missions requires analysis of a broad range of biomarkers and analytes including electrolytes, glucose, lipid profiles, stress and inflammatory markers, bone turnover proteins, and indicators of immune function and radiation damage.

[0119] Protein biosensors offer a promising solution, providing high specificity and rapid detection of these targets. Engineered to respond to specific analytes with measurable electrochemical or optical signals, these biosensors can be integrated into compact, automated systems that continuously assess astronaut health in mission, enabling early intervention and adaptive medical support in deep space.

[0120] In regard to supporting information to systems, apparatuses, devices, and methods in accordance with embodiments of the disclosures made herein, Table 2 discloses analytes to detect in standard blood panels using biosensors and redox potential (Pt) electrodes and Table 3 discloses various aspects of diagnostic assays.TABLE 2EasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsor?Well- 70- Enzyme establiGlucose Smal 14 -based Yes shed1 0 (GOx / F glucosmole mg AD) ecule / dL oxi das(fa esti biosenng) sorsexist.Coat lonop Pt hore Typicall with captu lon- y No a res Sodium selective measure direct Sodiu Na+,Ion 135-145 No(Na+) sensor d with redox m- causi mEq / L(nonion- activity select ng a protein) selective ive redox electrode ionop shift s. hore via (eg, electr crow on n transf ethers er 5 medi calixa ators.EasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsorrenes)Valin Better Modify omyci Ion- detected No Pt with n Potassiu Ion 3.5-5.0 selective No with direct Valino selecti m (K+) mEq / L sensor electroch redox mycin- vely (nonemi cal activity functio binds protein) sensors. nalized K+, film alterin g charg e transf er. Ca2+bindi Engineer Coul Mod ng ed d ify indue calcium- use a es a No Ptbinding w confo Calcium redo direct ithIon 8.5-10.2 Mayb rmati (Ca2+) protein X- redox Calmg / dL (Calmod e linke ona reach o mod l ulin d ch n ulin ang variant) conf or e thatEasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsororm iono can ation phor be al e coupl chan (eg, ed to ge- ETH redox signal 129) ing.AgC 1 Func form Ion- Not ideal No tiona ation Chloride Ion 96-106 selective No for strong lize alter (Cl ) sensor protein redox Pt s the mEq / L(nonbiosenso propert with redo protein) rs. ies Silve X r pote (Ag) ntial, nano enab parti ling cles indir ect meas urem ent. Conve Coat Pt rts with HCChEasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsorBicarb Usuall No Carbon ~ to onate direct ic CO2,Ion 22-28 pH- No y(HCO3measur redox Anhydr causin mEq / L sensitive) ed reactio asesensor g a indirec n enzym PH tly. e shift that affect s redox potent ial. Bloo Ureas Urease Immob Ure d Smal 6-24 e Yes -based No ilize ase Urea 1 mg / dL enzy detecti direct Urease con Nitro mole me on of redox enzym ver gen cule sensor ammon e on Pt ts (BU ia ure N) could a work. int 0 NH3 +c O2, shif tinEasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsorg pH and aff ecti ng red ox stat e. Conv Engine Use erts ered Possibl Creatin creati Creatini Smal 0.6-1.3 creatini Mayb e, but Weak ine nine ne 1 mg / dL ne- e may redox Deimin into mole binding need activity ase NH3, cule protein amplifi enzym whic cation. e on Pt h alters the local PH and redox state. Mayneed anEasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsorLipid- additionbiTota Lipid <200 ndingl Mayb alengineerCholeste mg / dL e enzymatrol ed icprotein reactionCouldLipid- detectTriglyce Lipid <150 binding Mayb oxidizerides mg / dL engineer e d lipidsed viaprotein redoxreaction.HDL Engineer Surface(High- Lipo >40 ed Mayb interactiDensity prote mg / dL HDL- e onsLipopr in binding might beotein) protein needed.MayLDL Engineer need a(Low- Lipo <100 ed Mayb nanopartDensit prote mg / dL LDL- e icle / enzy in binding ym eLipopr protein conjugatotein) e.EasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsor?<1 EngC- mg / dL ine GoodReactiv Prote (normal ere Yes Candidae in ), d te for aProtein CR biosens(CRP) 1 P- or0 bin array.m ding g / protd einL(infecti0n)<0.01ng / mL EngineeredEasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsor?Troponi Prote (no Tropo Yes Highlyn l / T in rm nin- relevantal), specifi for>0. c cardiac1 protein diagnostng / ics.mL(heartattack)<100pg / mL EnBrain (nor gin GoodNatri Prote mal eer Yes foruretic in ), ed heartPepti >40 BN failurede 0 P- diagn(BNP Pg / bin osis.) mL din(he gart profail teinure)Engin Couleered dEasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsor?Albumin Prote 3.5-5.0 Albu Yes tracin g / dL min- kbindin protg ein- protei enern gymetabolism.1-10pg / mL Engin HighCyto (norma eered relevankines Prote 1), 100- cytoki Yes ce in(IL- in 1000 ne- immun6, pg / mL bindin eTNF- (inflam g respona) mation protei se and) n inflammationHormon Engine Possiblees ng / mL ered but may(Cortisol Prote to hormo Yes needin pg / mL ne- additionThyroid range bindin al signalHormon g amplificprotein ation.EasilyDetectableby Mec Modific Typic Best Engi hani ation al Biosens neere sm Current Strateg Blood or d Analyte of Analyte Type Limitati y for Pt Rang Strateg Prote Notes Dete on Surface e y in ctio Biose n nsor?es,Insulin)Pathoge Engin Establin eered shedAntigen Prote Varies antig Yes conceps (e.g., in en- t withSARS- bindi highCoV-2 ng sensitivspike protei ity.protein) nTABLE 3Can It BeDiagnostic Target Best Biological Detected Type NotesMedia by anEngineeredProteinBiosensorLipid profiles Blood Yes Small Requires lipid- (cholesterol, molecule binding proteins triglycerides) or enzymes (e.g., cholesterolCan It BeDiagnostic Target Best Biological Detected Type Notes Media by anEngineeredProteinBiosensoroxidase).Biomarkers for Blood Yes Protein Troponin already cardiovascular stress used in (troponin, BNP) immunoassays;BNP is a peptide hormone detectable via engineered binding proteins. Calcium and Blood or Urine Indirectly Ion Requires phosphorus levels ion- selective proteinbased sensing (e.g., calcium- binding proteins)Bone turnover markers Blood Yes Protein Can be detected (osteocalcin, alkaline via specific phosphatase) antibodymimetic proteins. Biomarkers of DNA Blood Yes Protein y-H2AX can be damage (y-H2AX, targeted via micronuclei phospho-specific assays) protein binders. Oxidative stress Blood or Urine Yes Small Redox-active markers molecule proteins could (malondialdehyd detect oxidative e, 8-OHdG)Can It BeDiagnostic Target Best Biological Detected Type Notes Media by anEngineeredProteinBiosensorstress-induced changes.White blood cell count Blood No Cells Requires and differentials (Directly) alternative methods like flow cytometry or impedance sensing.Cytokine profiles (IL-6, Blood Yes Protein Engineered TNF-a) biosensors can detect inflammatory cytokines. Detection of reactivated Blood or Saliva Indirectly DNA Requires viruses (e.g., integration with herpesvirus DNA) DNA-binding proteins or aptamers.Urine osmolality, Urine Indirectly lon / Sma Creatinine can sodium, and creatinine 11 be detected levels molecul enzymatically e , sodium requires ionsensitive proteins.Electrolyte balance Blood Indirectly Ion Requires (sodium, potassium) ionophore or specialized protein for selectivity. Micronutrient levels Blood Yes Small Iron may require (iron, vitamin D, folate) molecule ferritin-basedCan It BeDiagnostic Target Best Biological Detected Type Notes Media by anEngineeredProteinBiosensorsensing; vitamin D / folate may need binding proteins.Protein and Blood Yes Protein Can be detected energy using binding metabolism domains or (albumin, immunoassayprealbumin) like systems. Pathogen identification Blood, Surface Yes Other Requires Swabs, or Air (Microbi engineered al) proteins targeting pathogenspecific surface markers. Surface swabs or air Surface Swabs or Yes Other Engineered samples for microbial Air Samples (Microbi biosensors can presence al) detect bacterial proteins or metabolites. Blood glucose levels Blood Yes Small Glucose oxidase (Fingerstick) molecule or alternative engineered proteins can be used.Hormonal assays Blood Yes Small Hormones can be (thyroid hormones, molecule detected with cortisol, insulin) / Protein receptor-based protein sensors. Lipid profiles for Blood Yes Small Similar to metabolism molecule general lipid profiling;Can It BeDiagnostic Target Best Biological Detected Type NotesMedia by anEngineeredProteinBiosensorrequires lipid- binding proteins. Neural activity or stress Blood Yes Protein Can be detected (SI 00 calcium -binding via specific protein) binding domains. Coagulation profiles Blood Yes Protein Fibrinogen and (PT / INR, fibrinogen clotting factors levels) can be targeted by engineered protein sensors.Infection markers (CRP, Blood Yes Protein CRP and procalcitonin) procalcitonin are well-established biomarkers detectable via engineered proteins.

[0121] Although the invention has been described with reference to several exemplary embodiments, it is understood that the words that have been used are words of description and illustration, rather than words of limitation. Changes may be made within the purview of the appended claims, as presently stated and as amended, without departing from the scope and spirit of the invention in all its aspects. Although the invention has been described with reference to particular means, materials and embodiments, the invention is not intended to be limited to theparticulars disclosed; rather, the invention extends to all functionally equivalent technologies, structures, methods and uses such as are within the scope of the appended claims.

Claims

CLAIMSWhat is claimed is:

1. A system, comprising:a medical diagnostic platform including a diagnostics device and a diagnostics device reader;wherein the diagnostics device includes on-board capability for performing diagnostic assay of aqueous specimens;wherein the diagnostics device reader engages with the diagnostics device to obtain assay results information generated by one or more diagnostic assays performed by the diagnostics device; andwherein the device reader interprets the assay results information and output information characterizing said interpretation of the assay results information.

2. The system of claim 1, wherein the diagnostics device includes one of a single protein biosensor and a plurality of protein biosensors.

3. The system of claim 1, wherein:the diagnostics device includes at least one protein biosensor; andthe at least one protein biosensor is a synthetic protein biosensor.

4. The system of claim 1, wherein:the diagnostics device includes a microfluidic sensor array chip comprising a plurality of protein biosensors;each of the protein biosensors is exposed to a microfluidic sensor array chip adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output;each of the protein biosensors provides redox -based signal transduction; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

5. The system of claim 4, wherein the selective microwell gating is provided for via selective generation of an electrolysis-driven gaseous bubble within a particular microwell.

6. The system of claim 1, wherein:the diagnostics device includes at least one protein biosensor; andthe at least one protein biosensor provides redox-based signal transduction.

7. The system of claim 6, wherein at least one of:the at least one protein biosensor is exposed to a microfluidic sensor array chip adapted to enable readout of said assay results information via one or more of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output;the microfluidic sensor array chip is a Complementary Metal Oxide Semiconductor (CMOS) microfluidic sensor array chip; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

8. The system of claim 7, whereina specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip;the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip; andeach reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

9. The system of claim 6, wherein:the at least one protein biosensor is a synthetic protein biosensor;the synthetic protein biosensor is exposed to a microfluidic sensor array chip adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

10. The system of claim 9, wherein the selective microwell gating is provided for via selective generation of an electrolysis-driven gaseous bubble within a particular microwell.

11. The system of claim 9, whereina specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip;the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip; andeach reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

12. The system of claim 6, wherein:the at least one protein biosensor is exposed to a microfluidic sensor array chip adapted to enable readout of said assay results information via one or more of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

13. The system of claim 12, whereina specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip;the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip; andeach reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

14. The system of claim 1, wherein:the diagnostics device includes at least one biosensor; andthe at least one biosensor is configured to perform an assay of a bodily fluid.

15. The system of claim 14, whereina specimen reservoir structure overlays an upper surface of a microfluidic sensor array chip of the at least one biosensor;the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip; andeach reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

16. The system of claim 1, wherein the diagnostics device includes a microfluidic sensor array chip.

17. The system of claim 16, wherein:the microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof; andthe microfluidic sensor array chip is adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output.

18. The system of clam 1, wherein:the diagnostics device includes at least one protein biosensor including a microfluidic sensor array chip;the at least one protein biosensor is a synthetic protein biosensor; andthe synthetic protein biosensor is exposed to a microfluidic sensor array chip adapted to enable readout of said assay results information.

19. The system of claim 18, wherein at least one of:the at least one protein biosensors provides redox-based signal transduction;the microfluidic sensor array chip is adapted to enable readout of said assay results information via one or more of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

20. The system of claim 18, wherein:the microfluidic sensor array chip is adapted to enable readout of said assay results information via one or more of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

21. The system of claim 20, wherein the selective microwell gating is provided for the selective generation of an electrolysis-driven gaseous bubble within a particular microwell.

22. The system of claim 18, wherein:a specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip;the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip; andeach reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

23. The system of claim 1, wherein:the diagnostics device includes at least one protein biosensor including a microfluidic sensor array chip; andthe microfluidic sensor array chip is a Complementary Metal Oxide Semiconductor (CMOS) microfluidic sensor array chip.

24. The system of claim 23, wherein the microfluidic sensor array chip is adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output.

25. The system of claim 24, whereina specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip;the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip; andeach reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

26. The system of claim 1, wherein:the diagnostics device includes at least one biosensor including a sensor array chip; and a microwell specimen body is engaged with an upper surface of the sensor array chip.

27. The system of claim 26, wherein the sensor array chip is adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output.

28. The system of claim 26, wherein the sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

29. The system of claim 28, wherein at least one of:the at least one biosensor provides redox-based signal transduction;the sensor array chip is adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output; andthe selective microwell gating is provided for via selective generation of an electrolysis- driven gaseous bubble within a particular micro well.

30. The system of claim 1, wherein:the diagnostics device includes at least one protein biosensor including a microfluidic sensor array chip; andthe microfluidic sensor array chip is adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output.

31. The system of claim 1, whereinthe diagnostics device includes at least one protein biosensor including a microfluidic sensor array chip; anda specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip.

32. The system of claim 31, wherein the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip.

33. The system of claim 32, wherein each reservoir well of the array of specimen reservoir wells encompasses a respective plurality of the microwells of the microfluidic sensor array chip.

34. The system of claim 31, wherein at least one of:the at least one protein biosensor is a synthetic protein biosensor;the at least one protein biosensors provides redox-based signal transduction;the microfluidic sensor array chip is adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output;the microfluidic sensor array chip is a Complementary Metal Oxide Semiconductor (CMOS) microfluidic sensor array chip; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

35. The system of claim 31, wherein:the at least one protein biosensor is a synthetic protein biosensor;the microfluidic sensor array chip is adapted to enable readout of said assay results information via at least one of light-based information output, surface plasmonresonance (SPR) based information output, and electrochemical based information output;the microfluidic sensor array chip is a Complementary Metal Oxide Semiconductor (CMOS) microfluidic sensor array chip; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

36. The system of claim 35, wherein the selective microwell gating is provided for via selective generation of an electrolysis-driven gaseous bubble within a particular microwell.

37. The system of claim 31, wherein:the microfluidic sensor array chip is adapted to enable readout of said assay results information via one or more of light-based information output, surface plasmon resonance (SPR) based information output, and electrochemical based information output; andthe microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

38. The system of claim 31, wherein the microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.The system of claim 38, wherein the selective microwell gating is provided for via selective generation of an electrolysis-driven gaseous bubble within a particular microwell.

39. The system of claim 1, wherein:the diagnostics device includes at least one protein biosensor including a microfluidic sensor array chip;a specimen reservoir structure overlays an upper surface of the microfluidic sensor array chip;the specimen reservoir structure includes an array of specimen reservoir wells each associated with one of a plurality of microwells of the microfluidic sensor array chip; andat least one of the diagnostics device and the device reader includes a mapping correlating each reservoir well of the array of specimen reservoir wells to the respective plurality of the microwells of the microfluidic sensor array chip encompassed thereby.

40. The system of claim 40, wherein the microfluidic sensor array chip is adapted to provide selective microwell gating for enabling access to selected microwells thereof.

41. The system of claim 41, wherein the selective microwell gating is provided for via selective generation of an electrolysis-driven gaseous bubble within a particular microwell.

42. The system of claim 1, wherein:the diagnostics device includes reference electrodes; andthe device reader is adapted to utilize said reference electrodes to calibrate and normalize a signal of the diagnostics device.

43. The system of claim 43, wherein said calibration includes statistical signal processing across reference wells.

44. The system of claim 44, wherein the statistical signal processing provides corrections including at least one of background subtraction, cross-contamination fdtering, carryover detection, and electrolysis-induced noise compensation.

45. The system according to any one of claims 1-45, wherein at least one of:the device reader provides multiplexing of a microfluidic sensor array chip of the diagnostics device across multiple patients utilizing specimen reservoir-to-microwell mapping functionality of the diagnostics device; andthe system further comprises an apparatus that receives information from at least one of the diagnostics device and device reader and provides multiplexing of the microfluidic sensor array chip of the diagnostic device across said multiple patients utilizing said specimen reservoir-to-microwell mapping functionality of the diagnostics device.

46. The system according to any one of claims 1-45, wherein:the diagnostic device includes a plurality of biosensors each exposed to a respective portion of a sensor array chip that senses chemical reaction of an analyte reacting with exposure to a respective one of the biosensors; andthe chip sensor receives an assay result signal corresponding to said chemical reaction of a respective one of the biosensors in response to detection of a target analyte by the respective one of the biosensors and produces an output signal corresponding to the assay result signal.

47. The system of claim 47, wherein the plurality of biosensors jointly defining an array of assay sites each having a common biosensor configuration to thereby form a localized detection zones on the sensor array chip for the target analyte.

48. The system according to any one of claims 1-45, wherein:protein of each biosensor includes a redox site comprising a redox-active moiety whose electron transfer to an electrode is structurally gated;in an unbound state, the moiety is conformationally sequestered from redox coupling; and upon analyte binding, a structural rearrangement occurs that results in the redox site enabling direct or mediator-assisted electron transfer to the embedded transducer.

49. The system of claim 49, wherein said analyte binding includes one of a cofactor and a redox mediator in surface chemistry of the redox site that participates in redox cycling of the redoxactive moiety to amplify signal output with each binding event through turnover of the mediator to thereby enable continuous electron release while analyte is present and analyte binding occurs.

50. The system of claim 49, wherein:the diagnostic device includes a plurality of biosensors each exposed to a respective portion of a sensor array chip that senses chemical reaction of an analyte reacting with exposure to a respective one of the biosensor;the sensor array chip includes a plurality of microwells;each one of the microwells includes one of the biosensors therein above a base of a respective one of the microwells;working electrodes are provided at a base of each of the microwells;electrons generated from the redox-active moiety are transferred to the working electrode where they are detected by a readout system of the sensor array chip to produce an output signal that is a function of said analyte binding; andthe output signal is measured based upon one of a current thereof, a potential shift thereof, and an impedance thereof.

51. The system according to any one of claims 1-45, wherein each protein biosensor is covalently immobilized onto an electrode surface to provide stable, long-term attachment and precise spatial localization thereof.

52. The system of claim 51, wherein said covalent immobilization includes functionalizing the electrode surface with self-assembled monolayers (SAMs)53. The system of claim 53, wherein the self-assembled monolayers (SAMs) include reactive groups thereon that form bonds with the protein biosensor.

54. The system of claim 52, wherein said covalent immobilization is performed to provide redox signal amplification and electron shuttling.

55. The system of claim 55, wherein said redox signal amplification and electron shuttling is performed using a phenothiazine derivative and reducing analyte.